RE:RE:AstraZeneca paid USD$ 5.5 Billion to co-market Enhertu Enhertu® is made up of two cancer-fighting agents: an antibody attached to chemotherapy.
Today Health Canada approved Enhertu for Her2-low metastatic breast cancer. Enhertu works by attacking cancer cells that have a Her2 protein on the cell surface and presents with side effects that are similar to those exhibited by chemotherapy, except to a lesser extent.
It is important to consider that many patients cannot tolerate chemotherapy regardless of the level of side-effects.
ONCY pelareorep on the otherhand, is directed at Her2-negative breast cancer, where no Her2 protein is detectable, and pelareorep is administered prior to the addition of an immune checkpoint inhibitor. The effect of pelareorep is that it remodels the TME and enhances T-cell stimulation through both an innate and adaptive immune response - in advance of the addition of an immune chcekpoint inhibitor - and is able to overcome the issue of T-cell exhaustion that is triggered by most other cancer therapies.
The side effects with pelareorep are minimal, and are usually manifested as short term flu-like symptoms.
https://www.biospace.com/article/releases/enhertu-and-8482-approved-by-health-canada-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer/